Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01065935 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Phase 2 study, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT01065935 is a Phase 2 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 87 participants.
The verdict
NCT01065935, a Phase 2 study, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of ALN-RSV01 plus standard of care in RSV infected lung transplant patients
Interventions
- DRUG Normal Saline
- DRUG ALN-RSV01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01065935
The ClinicalTrials.gov registry entry for NCT01065935 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.
NCT01065935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01065935 about?
NCT01065935 is a clinical study titled "Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)". To evaluate the efficacy and safety of ALN-RSV01 plus standard of care in RSV infected lung transplant patients
What is the current status of trial NCT01065935?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2010-02. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01065935?
The interventions under investigation include: Normal Saline (DRUG), ALN-RSV01 (DRUG).
Who is sponsoring clinical trial NCT01065935?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.